Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Tables)

6 Months Ended

Jun. 30, 2018

Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements

Disaggregation Of Revenue

In thousands of US dollars ($)		Three Months Ended June 30, 2018						Six Months Ended June 30, 2018
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68	$	—	$	68	$	136	$	—	$	136
Concentrate Products
Product Sales – Point-in-time		14,340		12,856		1,484		28,716		25,328		3,388
License Fee – Point-in-time		505		505		—		1,009		1,009		—
Total Concentrate Products		14,845		13,361		1,484		29,725		26,337		3,388
Net Revenue	$	14,913	$	13,361	$	1,552	$	29,861	$	26,337	$	3,524

Contract Balances

In thousands of US dollars ($)	June 30, 2018		December 31, 2017
Receivables, which are included in "Trade and other receivables"	$	5,360	$	5,544
Contract liabilities	$	15,578	$	16,723